2 mid-cap growth stocks with millionaire-maker potential

These two growth stocks are highly defensive and have plans for explosive growth.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Trying to find defensive growth stocks is a difficult, but not impossible task. For example, in the healthcare sector, there are plenty of opportunities for investors. One example is Spire (LSE: SPI). 

An opportunity to buy? 

Shares in Spire are falling today after it was revealed that the company is no longer in merger talks with larger peer Mediclinic International. Even though Mediclinic was interested in its smaller peer, it seems that the two parties couldn’t agree on a price, which resulted in merger talks breaking down. 

Commenting on the breakdown, Spire Chairman Garry Watts said: “The board carefully considered Mediclinic’s approach but determined that it did not reflect the true value of the company and was not in the best interests of shareholders as a whole.

I believe that this is an excellent opportunity for investors. Spire is the most significant leading independent hospital group in the UK with 39 private hospitals, 10 clinics and two Specialist Cancer Care Centres. 

Over the past few years, management has capitalised on its unique position in the market by expanding its offering into new regions and acquiring smaller peers. Several new premises are being opened this year. Initially these will hold back earnings growth, but City analysts expect the company’s spending to begin to pay off in 2018. After falling by 22% in 2017, analysts are predicting 5% earnings per share growth for 2018. 

Even though this near-term outlook might not look attractive, I believe that over the long term, Spire will become a millionaire-maker stock. The firm is well positioned to grow in the UK market and management has a record of profitable growth. That being said, there are some concerns about the firm’s exposure to the NHS

Meanwhile, the shares trade at a forward P/E of only 18, below the Healthcare Providers & Services Industry sector average of 23. There’s a dividend yield of only 1.3% on offer but the payout is covered four times by earnings per share, leaving plenty of room for further rises. 

As Spire returns to growth, I believe the shares should re-rate and when management decides to slow the company’s expansion plan, shareholder returns should quickly materialise. 

Emerging market growth 

Spire has many attractive qualities, but for those investors who are willing to take more risk by investing overseas, Georgia Healthcare (LSE: GHG) might be a better buy. 

Listed in London, it offers exposure to the fast-growing economy of Georgia via the healthcare sector. The business is one of the largest in the industry and its size (as well as vertical integration) is helping to accelerate growth. 

For the first nine months of the year, it reported a 44% increase in EBITDA and a 26% increase in profit before tax. For the full year, City analysts have pencilled in a 22% decline in earnings per share, thanks to the ramp-up in spending on capital projects. 

However for 2018, growth is expected to return with a vengeance. Earnings per share are projected to rise 91% year-on-year to 17.9p giving a forward P/E of 21. Compared to Spire, this valuation might look expensive, but when you factor-in growth, the shares are trading at a PEG ratio of 0.2, which is exceptionally cheap. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves has no position in any share mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »